[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-alcoholic-steato-hepatitis-nash\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-alcoholic-steato-hepatitis-nash":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100580887","stimulating-fat-tissue-storage-with-niacin-to-reduce-fat-accumulation-in-the-liver-100580887",false,"NCT06843148","Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.","Stimulating Adipose Tissue Fatty Acid Disposal With Low-dose, Postprandial, Intermittent Niacin for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).","AGL13","Inclusion Criteria:\n\n* aged 20 to 80 years;\n* diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country\u002Fethnic group-specific criteria;\n\nExclusion Criteria:\n\n1\\) Presence of advanced fibrosis using any of the following criteria 1.1 (i.e., ≥ F3 based on liver stiffness \\> 10kPa) using vibration-controlled transient elastography (FibroScan), 1.2 (Index for Liver Fibrosis \\> 2.67) using Fibrosis-4 (FIB-4) which is a calculated score based on age and a combination of lab tests (aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], and platelet count), 1.3 serum ALT \\> 3 times the normal upper limit, 1.4 or signs of portal hypertension. 2) Other hepatic disease. 4) Overt cardiovascular or renal disease, cancer (other than non-melanoma skin cancer), or other uncontrolled medical conditions.\n\n5\\) Any contraindication to MRI. 6) Previous intolerance or allergy to nicotinic acid. 7) Having participated to a research study with exposure to radiation in the last two years before the start of the study.\n\n8\\) Being allergic to eggs 9) Smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day.\n\n10\\) Women who are pregnant or breastfeeding.","ALL","20 Years","80 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation\u002F fibrosis. MASLD results from fat being disproportionately deposited in the liver.\n\nThe goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment.\n\nThe main questions it aims to answer are:\n\n* Does Niacin lower the fat deposition in the liver?\n* Does Niacin raise White Adipose Tissue storage of dietary fatty acids?\n\nResearchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response.\n\nDuration of study per participant: Up to 28 weeks",[28,29,30],"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Liver Fibrosis\u002FNASH","Non-Alcoholic Steato-Hepatitis (NASH)",[32,33,34,35],"Fatty liver","Niacin","vitamin B3","nicotinic acid","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-06-22",{"date":44,"type":22},"2030-07",{"name":46,"class":47},"Université de Sherbrooke","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100603233","how-abnormal-function-of-fat-tissue-in-type-1-diabetes-contributes-to-fat-in-the-liver-100603233","NCT07133854","How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver","The Impact of Adipose Tissue Insulin Resistance and Abdominal Obesity on Hepatic Fatty Acid Metabolism in Type 1 Diabetes","AGL14","Inclusion Criteria:\n\n* 16 individuals living with T1D and abdominal obesity, as defined by the International Diabetes Federation country\u002Fethnic group-specific criteria (https:\u002F\u002Fwww.idf.org\u002Fe-library\u002Fconsensus-statements\u002F60- \\[1\\]. Treatment for T1D will be intensive insulin therapy on continuous pump perfusion with continuous glucose monitoring.\n* 16 individuals with normoglycemia (i.e., HbA1c below 6.0%) matched for sex, age (± 5 years), waist circumference (± 3 cm), and menopausal status.\n\nExclusion Criteria:\n\n* less than 70% of time in glycemic range (for T1D);\n* history of primary dyslipidemia (LDL-cholesterol over 5 mmol\u002FL or TG over 10 mmol\u002FL) or uncontrolled high blood pressure (over 160\u002F100 mmHg) precluding the withdrawal of lipid lowering and anti-hypertensive agents as per protocol;\n* presence of overt cardiovascular, liver or renal disease (except microalbuminuria without reduced kidney function), or other uncontrolled medical conditions;\n* use of any medication other than insulin that may affect lipid or carbohydrate metabolism and that cannot be stopped prior to testing;\n* current or planned pregnancy within the next 6 months;\n* any contraindication to MRI.\n* Being allergic to eggs\n* Smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day\n* Having participated to a research study with exposure to radiation in the last year before the start of the study",true,"21 Years",{"count":60,"type":22},32,[25],"Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.",[64,30,65],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Type 1 Diabetes Mellitus",[67,68],"abdominal obesity","Adipose tissue insulin resistance","NOT_YET_RECRUITING","2025-08-13",{"date":72,"type":40},"2025-08-21",{"date":74,"type":22},"2026-09",{"date":76,"type":22},"2028-12",{"name":46,"class":47}]